Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a potent and selective vascular endothelial cell mitogen and angiogenic factor. VEGF expression is elevated in a wide variety of solid tumors and is thought to support their growth by enhancing tumor neovascularization. To block VEGF-dependent angiogenesis, tumor cells were transfected with cDNA encoding the native soluble FLT-1 (sFLT-1) truncated VEGF receptor which can function both by sequestering VEGF and, in a dominant negative fashion, by forming inactive heterodimers with membrane-spanning VEGF receptors. Transient transfection of HT-1080 human fibrosarcoma cells with a gene encoding sFLT-1 significantly inhibited their implantation and growth in the lungs of nude mice following i.v. injection and their growth as nodules from cells injected s.c. High sFLT-1 expressing stably transfected HT-1080 clones grew even slower as s.c. tumors. Finally, survival was significantly prolonged in mice injected intracranially with human glioblastoma cells stably transfected with the sflt-1 gene. The ability of sFLT-1 protein to inhibit tumor growth is presumably attributable to its paracrine inhibition of tumor angiogenesis in vivo , since it did not affect tumor cell mitogenesis in vitro . These results not only support VEGF receptors as antiangiogenic targets but also demonstrate that sflt-1 gene therapy might be a feasible approach for inhibiting tumor angiogenesis and growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Kendall, R. L., & Thomas, K. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10705 · Cited by 1,394
Self-citationBarleon, B., Sozzani, S., Zhou, D., Weich, H., Mantovani, A., & Marme, D. (1996) · Blood · doi:10.1182/blood.v87.8.3336.bloodjournal8783336 · Cited by 1,356
Cited by
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Molecular and biological properties of vascular endothelial growth factor
Ferrara, N. (1999) · Journal of Molecular Medicine · doi:10.1007/s001099900019 · Cited by 1,158
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004
“Furthermore, high local expression of the soluble extracellular domain of VEGFR-1 or VEGFR-2, achieved by administration of the recombinant proteins, adenoviral-mediated gene transfer or by stable transfection of tumor cells, may significantly inhibit tumor growth, metastasis and mortality rate in nude mic”
BackgroundRegulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
“Recent studies indicate that inhibition of tumor-derived VEGF expression restricts angiogenesis and promotes vascular regression in experimental tumor models (Kim et al. 1993; Millauer et al. 1994, 1996; Warren et al. 1995; Goldman et al. 1998).”
Backgroundp53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y., Harada, M., et al. (2007) · Nature · doi:10.1038/nature05602 · Cited by 905
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Mancuso, M. R., Davis, R., Norberg, S. M., O'Brien, S., Sennino, B., Nakahara, T., Yao, V. J., Inai, T., Brooks, P., Freimark, B., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24612 · Cited by 809
Mäkinen, T., Jussila, L., Veikkola, T., Karpanen, T., Kettunen, M. I., Pulkkanen, K. J., Kauppinen, R., Jackson, D. G., Kubo, H., Nishikawa, S.-I., et al. (2001) · Nature Medicine · doi:10.1038/84651 · Cited by 777
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Angiogenesis: regulators and clinical applications
Liekens, S., De Clercq, E., & Neyts, J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00529-3 · Cited by 748
Holash, J., Wiegand, S. J., & Yancopoulos, G. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203035 · Cited by 744
Role of vascular endothelial growth factor in the regulation of angiogenesis
Ferrara, N. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00610.x · Cited by 731
Gerety, S. S., Wang, H. U., Chen, Z.-F., & Anderson, D. J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80342-1 · Cited by 707
Veikkola, T., Jussila, L., Makinen, T., Karpanen, T., Jeltsch, M., Petrova, T. V., Kubo, H., Thurston, G., McDonald, D. M., Achen, M. G., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1223 · Cited by 663
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
Sugimoto, H., Hamano, Y., Charytan, D., Cosgrove, D., Kieran, M., Sudhakar, A., & Kalluri, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300012200 · Cited by 538
VEGF Receptor Signaling in Tumor Angiogenesis
McMahon, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-3 · Cited by 519
A Mechanism for Modulation of Cellular Responses to VEGF Activation of the Integrins
Byzova, T. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00083-6 · Cited by 438
Vasculogenesis and Angiogenesis
Patan, S. (2004) · Cancer Treatment and Research · doi:10.1007/978-1-4419-8871-3_1 · Cited by 430
The role of VEGF receptors in angiogenesis; complex partnerships
Cébe-Suarez, S., Zehnder-Fjällman, A., & Ballmer-Hofer, K. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5426-3 · Cited by 405
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prieto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 383
Vasculogenesis and Angiogenesis as Mechanisms of Vascular Network Formation, Growth and Remodeling
Patan, S. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006493130855 · Cited by 382
Inoki, I., Shiomi, T., Hashimoto, G., Enomoto, H., Nakamura, H., Makino, K.-I., Ikeda, E., Takata, S., Kobayashi, K.-I., & Okada, Y. (2002) · The FASEB Journal · doi:10.1096/fj.01-0332fje · Cited by 372
Hashimoto, G., Inoki, I., Fujii, Y., Aoki, T., Ikeda, E., & Okada, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201674200 · Cited by 339
Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer
Gasparini, G. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2004-37 · Cited by 322
Gagnon, M. L., Bielenberg, D. R., Gechtman, Z., Miao, H.-Q., Takashima, S., Soker, S., & Klagsbrun, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040337597 · Cited by 313
Neuropilin‐1 expression by tumor cells promotes tumor angiogenesis and progression
Miao, H., Lee, P., Lin, H., Soker, S., & Klagsbrun, M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0250com · Cited by 312
Hiasa, K.-I., Ishibashi, M., Ohtani, K., Inoue, S., Zhao, Q., Kitamoto, S., Sata, M., Ichiki, T., Takeshita, A., & Egashira, K. (2004) · Circulation · doi:10.1161/01.cir.0000128213.96779.61 · Cited by 308
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Cao, Y. (2009) · Science Signaling · doi:10.1126/scisignal.259re1 · Cited by 289
Vascular endothelial growth factor and endometriotic angiogenesis
McLaren, J. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.1.45 · Cited by 269
Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
Saaristo, A., Karpanen, T., & Alitalo, K. (2000) · Oncogene · doi:10.1038/sj.onc.1203969 · Cited by 264
Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1)
Shibuya, M. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00026-7 · Cited by 260
Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253
Klagsbrun, M., & Moses, M. A. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80081-7 · Cited by 237
Endogenous angiogenesis inhibitors and their therapeutic implications
Cao, Y. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00023-1 · Cited by 228
Lafky, J. M., Wilken, J. A., Baron, A. T., & Maihle, N. J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.01.001 · Cited by 215
Ebos, J. M. L., Bocci, G., Man, S., Thorpe, P. E., Hicklin, D. J., Zhou, D., Jia, X., & Kerbel, R. S. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.315.2.6 · Cited by 211
“colorectal carcinoma (27), renal cell carcinoma (28), fibroscarcoma (29), and astrocytic tumors (30) as well as for its possible contribution to diseases such as preeclampsia (31, 32).”
BackgroundRossignol, M., Gagnon, M. L., & Klagsbrun, M. (2000) · Genomics · doi:10.1006/geno.2000.6381 · Cited by 200
Folkman, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9064 · Cited by 198
Zhao, Q., Ishibashi, M., Hiasa, K.-I., Tan, C., Takeshita, A., & Egashira, K. (2004) · Hypertension · doi:10.1161/01.hyp.0000138688.78906.6b · Cited by 177
Chiarotto, J. A., & Hill, R. P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690555 · Cited by 46
Metadata
- Authors
- Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., Thomas, K. A., & Curiel, D. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-07-21
- Volume
- 95
- Issue
- 15
- Pages
- 8795-8800
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2098671787
- Cited by
- 443
- References
- 43
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.